CD274 and non-small cell lung carcinoma: Furthermore, this benefit appears greater in patients with NSCLC and PD-L1 TPS expression ≥50% with brain metastases at baseline, with a 33% reduction in risk of death; median OS was 19.7 and 9.7 months, respectively.